MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is making progress in developing an AI-driven voice analysis technology aimed at detecting intoxication from alcohol and drugs, as outlined in a recent appearance on the TechMediaWire Podcast. The company’s prediction models are trained on over 50 million data points collected from years of clinical and behavioral research, positioning the technology for potential use in high-risk workplace environments.
During the podcast, MindBio Founder and CEO Justin Hanka discussed how the company’s speech analytics and machine learning systems identify physiological indicators of intoxication through non-invasive voice analysis. The platform can detect not only alcohol but also drugs affecting the central nervous system, including cannabis, cocaine, opioids, and psychedelics.
MindBio’s initial commercial strategy targets workplace safety sectors such as mining, aviation, and construction, where impairment-related incidents carry significant operational and regulatory risks. Management expects live workplace testing deployments to begin later in the second quarter of 2026 as the company transitions from development to commercial implementation. For more details on the podcast discussion, visit this link.
Hanka emphasized that the voice-analysis platform is part of a broader AI-driven diagnostics technology capable of supporting future health and wellness applications beyond intoxication monitoring. The company has spent several years conducting drug and alcohol research while collecting extensive speech and voice datasets through clinical studies and related programs. As AI and machine-learning systems have improved, MindBio believes it has developed models capable of reliable detection. Additional information on the technology can be found here.
The development comes as industries seek non-invasive, rapid methods to ensure worker safety. MindBio’s approach could offer an alternative to traditional breathalyzers or saliva tests, potentially reducing delays and improving compliance. The company views its technology as a tool that could be integrated into existing safety protocols, providing real-time assessments without requiring physical samples.
MindBio Therapeutics is a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection. The company’s newsroom provides updates on its progress at https://ibn.fm/MBQIF.
